IN8bio, Inc. (INAB)

Market Cap	44.59M
Revenue (ttm)	n/a
Net Income (ttm)	-30.01M
Shares Out	43.29M
EPS (ttm)	-1.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	267,815
Open	1.020
Previous Close	1.050
Day's Range	0.990 - 1.090
52-Week Range	0.650 - 3.950
Beta	-0.01
Analysts	Strong Buy
Price Target	9.30 (+802.91%)
Earnings Date	May 10, 2024

About INAB

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of solid and liquid tumors. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM and other cancers; and INB-100, an allogeneic product candidate, which is in Phase I clin...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 30, 2021
• Employees: 31
• Stock Exchange: NASDAQ
• Ticker Symbol: INAB

Analyst Forecast

According to 5 analysts, the average rating for INAB stock is "Strong Buy." The 12-month stock price forecast is $9.3, which is an increase of 802.91% from the latest price.

Price Target

$9.3

(802.91% upside)

Analyst Consensus: Strong Buy